- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
FLT3 targeting in the modern era: from clonal selection to combination therapies ; day:19 ; month:12 ; year:2023 ; pages:1-13
International journal of hematology ; (19.12.2023), 1-13
- Creator
-
Kennedy, Vanessa E.
Smith, Catherine C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-023-03681-0
- URN
-
urn:nbn:de:101:1-2024030321101533444470
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kennedy, Vanessa E.
- Smith, Catherine C.
- SpringerLink (Online service)
Other Objects (12)
Surgery in the combination therapies era
Resistance to targeted therapies: delving into FLT3 and IDH
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Nanomedicine formulations for combination therapies
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Combination therapies utilizing neoepitope-targeted vaccines
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Combination therapies enhance immunoregulatory properties of MIAMI cells
CAR-T cell combination therapies in hematologic malignancies
Surgery in the combination therapies era
Resistance to targeted therapies: delving into FLT3 and IDH
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Nanomedicine formulations for combination therapies
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Combination therapies utilizing neoepitope-targeted vaccines
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Combination therapies enhance immunoregulatory properties of MIAMI cells
CAR-T cell combination therapies in hematologic malignancies
Surgery in the combination therapies era
Resistance to targeted therapies: delving into FLT3 and IDH
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Nanomedicine formulations for combination therapies
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Combination therapies utilizing neoepitope-targeted vaccines
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Combination therapies enhance immunoregulatory properties of MIAMI cells